Membership Directory - Corporate
Taos Therapeutics
About
At Taos Therapeutics, our mission is to innovate and advance pharmaceuticals for the betterment of those suffering from substance use disorders.
Alcohol Use Disorder (AUD) kills ~178k Americans every year. Current FDA-approved medications (naltrexone, acamprosate, disulfiram) are poorly adopted and only modestly effective.
There is still no true adequate first-line treatment.
We are committed to developing cutting-edge therapies that address critically unmet medical needs while delivering superior ROI.
Fast to Market: streamlined 505(b)(2) regulatory path compresses timeline and costs.
Market Potential: First superior-efficacy drug could dominate an >$35B global market; and truly revolutionize treatment for a devastating disease with high morbidity and mortality as well as socioeconomic costs.
Capital Efficiency: low initial R&D spend = high leverage on investment.
Alcohol Use Disorder (AUD) kills ~178k Americans every year. Current FDA-approved medications (naltrexone, acamprosate, disulfiram) are poorly adopted and only modestly effective.
There is still no true adequate first-line treatment.
We are committed to developing cutting-edge therapies that address critically unmet medical needs while delivering superior ROI.
Fast to Market: streamlined 505(b)(2) regulatory path compresses timeline and costs.
Market Potential: First superior-efficacy drug could dominate an >$35B global market; and truly revolutionize treatment for a devastating disease with high morbidity and mortality as well as socioeconomic costs.
Capital Efficiency: low initial R&D spend = high leverage on investment.
